
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): April 5, 2016

Tandem Diabetes Care, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-36189
(Commission
File Number)

20-4327508
(I.R.S. Employer
Identification No.)

11045 Roselle Street, San Diego, CA
(Address of principal executive offices)

92121
(Zip Code)

Registrant's telephone number, including area code: (858) 366-6900

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Director

On April 5, 2016, Dr. Henry Anhalt, DO, FACOP, FACE, notified Tandem Diabetes Care, Inc. (the “Company”) of his resignation as a director, effective immediately. Dr. Anhalt has served as a director since March 2016. Dr. Anhalt’s decision to resign did not involve any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Prior to his resignation, Dr. Anhalt was serving as a Class II director and, as a result, his re-election as a director is not being considered or voted upon at the Company’s 2016 Annual Meeting of Stockholders to be held on May 11, 2016.

Issuance of Press Release

On April 8, 2016, the Company issued a press release announcing the aforementioned change to the board of directors. The press release is attached hereto as Exhibit 99.1 and is being “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Number Description

99.1 Press release of Tandem Diabetes Care, Inc. dated April 8, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Tandem Diabetes Care, Inc.

Date: April 8, 2016

/s/ David B. Berger

David B. Berger

Executive Vice President, General Counsel and Secretary

INDEX TO EXHIBITS

Number **Description**

99.1 Press release of Tandem Diabetes Care, Inc. dated April 8, 2016.

Media Contact:

Steve Sabicer
714-907-6264
ssabicer@thesabicergroup.com

Investor Contact:

Susan Morrison
858-366-6900 x7005
smorrison@tandemdiabetes.com

FOR IMMEDIATE RELEASE

**Dr. Henry Anhalt to Step Down From Tandem Diabetes Care Board of Directors
to Ensure No Risk of Potential Conflict of Interest**

San Diego, April 8, 2016 – Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim®, t:slim G4™ and t:flex® Insulin Pumps, today announced that Henry Anhalt, DO, FACOP, FACE has stepped down from its board of directors. Dr. Anhalt is chief medical officer of T1D Exchange, a program of the nonprofit organization Unitio, that fosters collaboration among patients, physicians, researchers and industry to speed discovery of better therapies for type 1 diabetes. Prior to his appointment in March 2016, Dr. Anhalt had the support of T1D Exchange to serve on Tandem’s Board. The non-profit’s governing body had conducted a thorough review of any risk of potential for conflict of interest. Following the announcement of Dr. Anhalt’s appointment to Tandem’s Board, T1D Exchange received member concerns about potential conflicts of interest, and as a result, Dr. Anhalt has notified Tandem that he regrettably is no longer able to serve on its board of directors.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. The Company manufactures and sells the t:slim® Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, the t:flex® Insulin Pump, the first pump designed for people with greater insulin requirements, and the t:slim G4™ Insulin Pump, the first CGM-enabled pump with touch-screen simplicity. Tandem is based in San Diego, California.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use #tslim, #tslimG4, #tflex, #tconnect, and \$TNDM.

Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.

Follow Tandem Diabetes Care on LinkedIn at <https://www.linkedin.com/company/TandemDiabetes>.

t:slim, t:flex and Tandem Diabetes Care are registered trademarks, and t:slim G4 is a trademark of Tandem Diabetes Care, Inc.

###